Universität zu Köln

Rits, Juris ORCID: 0000-0001-5696-7163, Maurins, Uldis ORCID: 0000-0002-5152-6737, Rabe, Eberhard ORCID: 0000-0002-2436-7697, Kadiss, Arnolds, Prave, Sandra, Vigants, Rets, Brunenieks, Ints ORCID: 0000-0001-9322-0835 and Pannier, Felicitas (2022). Lower prevalence of stump reflux after endovenous laser flush ablation of the great saphenous vein: A single center prospective randomized study. Vasa, 51 (4). S. 222 - 229. BERN: HOGREFE AG-HOGREFE AG SUISSE. ISSN 1664-2872

Full text not available from this repository.

Abstract

Background: This single center prospective randomized study was performed to compare the effect of endovenous laser flush ablation (EVLAf) of the great saphenous vein (GSV) close to the sapheno-femoral junction (SFJ) with a standard ablation (EVLAs) up to two cm distally of the SFJ on reflux in the GSV stump. Patients and methods: Between April 2013 and January 2016, 146 legs in 146 consecutive patients, meeting the inclusion/exclusion criteria, were treated by EVLA. All patients were randomized into 2 groups. In group 1 EVLAf started from the SFJ level, and in group 2 EVLAs started two cm below the SFJ. The primary endpoint was reflux in the GSV stump after 900 days. Secondary endpoints were reflux in the anterior accessory saphenous vein (AASV), proximal clinically recurrent varicose veins related to reflux in the stump and/or the AASV. Results: At day 900, 27 patients were lost to follow-up. Reflux in the stump was detected in 3.6% in group 1 and in 22.2% in group 2 (p<0.05). Reflux in the AASV was present in 7.1% in group 1 and in 17.46% in group 2 (p=0.09). Proximal clinically recurrent varicose veins were observed in 8.9% in group 1 and in 19.1% in group 2 (p=0.12). The greatest diameter of the stump was significantly larger in group 2 (group 1: 0.41 cm, group 2: 0.6 cm, p<0.001). Conclusions: EVLAf is associated with a significantly lower incidence of reflux in the GSV stump, with a trend to a lower incidence of reflux in the AASV and with a lower incidence of proximal recurrent varicose veins after 900 days follow-up compared to EVLAs. EVLAf may improve the clinical recurrence rate after EVLA of the GSV.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Rits, Juris UNSPECIFIED orcid.org/0000-0001-5696-7163 UNSPECIFIED Maurins, Uldis UNSPECIFIED orcid.org/0000-0002-5152-6737 UNSPECIFIED Rabe, Eberhard UNSPECIFIED orcid.org/0000-0002-2436-7697 UNSPECIFIED Kadiss, Arnolds UNSPECIFIED UNSPECIFIED UNSPECIFIED Prave, Sandra UNSPECIFIED UNSPECIFIED UNSPECIFIED Vigants, Rets UNSPECIFIED UNSPECIFIED UNSPECIFIED Brunenieks, Ints UNSPECIFIED orcid.org/0000-0001-9322-0835 UNSPECIFIED Pannier, Felicitas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-663385
DOI:	10.1024/0301-1526/a001007
Journal or Publication Title:	Vasa
Volume:	51
Number:	4
Page Range:	S. 222 - 229
Date:	2022
Publisher:	HOGREFE AG-HOGREFE AG SUISSE
Place of Publication:	BERN
ISSN:	1664-2872
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language AMERICAN VENOUS FORUM; 5-YEAR FOLLOW-UP; NM DIODE-LASER; CONTROLLED-TRIAL; VARICOSE-VEINS; HIGH LIGATION; RECURRENCE; CLASSIFICATION; SOCIETY; SURGERY Multiple languages Peripheral Vascular Disease Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66338